<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30384806</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1533-0338</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>17</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Jan</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Technology in cancer research &amp; treatment</Title>                <ISOAbbreviation>Technol. Cancer Res. Treat.</ISOAbbreviation>            </Journal>            <ArticleTitle>MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS.</ArticleTitle>            <Pagination>                <MedlinePgn>1533033818809997</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1533033818809997</ELocationID>            <Abstract>                <AbstractText>In recent study, microRNAs have various important functions in diverse biological processes and progression of cancer. In human breast cancer, microRNA-22 has been reported to be downregulated. However, molecular mechanism of microRNA-22 in breast cancer progression and chemosensitivity has not been well studied. In our study, these results demonstrated that microRNA-22 expression levels were significantly reduced in 40 pairs of human breast cancer tissues when compared to normal tissues. Enforced expression of microRNA-22 inhibited activity of cell proliferation and cell migration in breast cancer cells. Furthermore, microRNA-22 targeted NRAS proto-oncogene, GTPase (NRAS) in breast cancer cells. The expression levels of NRAS in human clinical specimens were higher in breast cancer tissues when compared to normal tissues. Moreover, microRNA-22 sensitized breast cancer cells to paclitaxel by regulation of NRAS. Our results then demonstrated that microRNA-22 functioned as a tumor suppressor microRNA and indicated potential application for the diagnosis and treatment of cancer in the future.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Song</LastName>                    <ForeName>Ying-Kui</ForeName>                    <Initials>YK</Initials>                    <AffiliationInfo>                        <Affiliation>1 Intensive Care Unit, Jining No. 1 People's Hospital, Jining, Shandong Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Breast and Thyroid, Jining No. 1 People's Hospital, Jining, Shandong Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wen</LastName>                    <ForeName>Yi-Yang</ForeName>                    <Initials>YY</Initials>                    <AffiliationInfo>                        <Affiliation>3 Department of Pathology, Jining No. 1 People's Hospital, Jining, Shandong Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Pei</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Breast and Thyroid, Jining No. 1 People's Hospital, Jining, Shandong Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bian</LastName>                    <ForeName>Zhi-Jie</ForeName>                    <Initials>ZJ</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-4415-906X</Identifier>                    <AffiliationInfo>                        <Affiliation>2 Department of Breast and Thyroid, Jining No. 1 People's Hospital, Jining, Shandong Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Technol Cancer Res Treat</MedlineTA>            <NlmUniqueID>101140941</NlmUniqueID>            <ISSNLinking>1533-0338</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">NRAS</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">miR-22</Keyword>            <Keyword MajorTopicYN="N">paclitaxel</Keyword>            <Keyword MajorTopicYN="N">tumor suppressor</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30384806</ArticleId>            <ArticleId IdType="doi">10.1177/1533033818809997</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>